Results 211 to 220 of about 1,459,127 (309)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

The broad societal value of pembrolizumab for women's cancer in Canada. [PDF]

Future Oncol
Brook E, Patterson K, Wijenayake N, Madin-Warburton M, Mishkin K, Meilleur MC, Davies A, Young K.   +7 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Selected Methods for Designing Monetary and Fiscal Targeting Rules Within the Policy Mix Framework. [PDF]

Entropy (Basel)
Przybylska-Mazur A.
europepmc   +1 more source

Bonding social capital, disaster experience, and post-disaster giving in Japan. [PDF]

Disasters
Okubo T, Noy I.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Modulating the Interplay Between Impulsivity and Interoception Through HD-tDCS to the Right Insula and Anterior Cingulate Cortex. [PDF]

Biomedicines
Pirone R, Gorrino I, Vedani A, Maiocchi C, Mattavelli G.   +4 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Dementia prevention requires moving beyond individual choice: the costs of effort and time intersect with social determinants of health. [PDF]

Neuroscience
Migeot J, Araya-Ríos D, Montecinos M, Baez S, Behrens MI, Castaner O, Cruzat J, Delgado C, De Jong-Bambagioni D, Duran-Aniotz C, Durón Reyes DE, Evans TE, Gonzalez-Gomez R, Gutiérrez M, Hayden KM, Hernandez H, Ibanez A, Legaz A, Miller J, Mačiulskytė S, Putthinun P, Santamaría-García H, Slachevsky A, Trépel D.   +23 more
europepmc   +1 more source